- American City Business Journals•10 hours ago
The World Health Organization said Monday that the world’s first malaria vaccine, which features a key component made by Lexington biotech Agenus, will be available in parts of Africa beginning next year. The WHO’s African regional office said that Ghana, Kenya and Malawi would participate in a pilot program for the injectable vaccine, which was developed by U.K. drug giant GlaxoSmithKline (GSK) with funding from the Bill & Melinda Gates Foundation. The vaccine contains a so-called adjuvant made by Agenus (AGEN), which is designed to boost the body’s immune response.
- Fool.co.uk•12 hours ago
These two different stocks in the same sector strike a happy balance, says Harvey Jones.
- Reuters - UK Focus•19 hours ago
Ghana, Kenya and Malawi will pilot the world's first malaria vaccine from 2018, offering it for babies and children in high-risk areas as part of real-life trials, the World Health Organization said on Monday. The injectable vaccine, called RTS,S or Mosquirix, was developed by British drugmaker GlaxoSmithKline (Other OTC: GLAXF - news) to protect children from the most deadly form of malaria in Africa. The WHO, which is in the process of assessing whether to add the shot to core package of WHO-recommended measures for malaria prevention, has said it first wants to see the results of on-the-ground testing in a pilot programme.
GLAXF: Summary for GLAXOSMITHKLINE PLC - Yahoo Finance
GlaxoSmithKline plc (GLAXF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
|Day's range||20.00 - 20.05|
|52-week range||18.16 - 22.24|
Trade prices are not sourced from all markets
|PE ratio (TTM)||86.21|
|Dividend & yield||0.95 (5.02%)|
|1y target est||N/A|